Bioventus price to free cash flow BVS
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Nov 2, 2026
- 11.7×
- 5-year median
- 24.9×
- Against its 5-year history
- 19th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 7.1× to 216×
- Peer median
- 18.3×
Bioventus' price to free cash flow is 11.7× as of Nov 2, 2026.
That is below its 5-year median of 24.9×, lower than on 81% of days in the last 5 years.
Over that time it ranged from 7.1× in May 2026 to 216× in Jul 2024.
The median for 10 medical instruments and supplies stocks of a similar size is 18.3×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 11.7× | 7.1× | 13.6× |
| 2025 | 11.5× | 11.0× | 29.8× |
| 2024 | 29.7× | 29.7× | 216× |
| 2023 | 38.6× | 29.0× | 45.4× |
| 2022 | 61.9× | 42.7× | 68.9× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| BVSBioventus | 11.7× |
| IARTIntegra Lifesciences | 12.3× |
| IRMDIradimed | 38.9× |
| STAAStaar Surgical | n/m |
| CDRECadre | 17.3× |
| EYENational Vision | 27.6× |
| MOVMovado | 10.0× |
| LMATLemaitre Vascular | 25.2× |
| INSPInspire Medical Systems | 16.6× |
| UFPTUFP Technologies | n/m |
| TCMDTactile Systems Technology | 19.3× |
| Peer median | 18.3× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Bioventus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.